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Objectives Prenatal screening for Down syndrome has become standard practice in many western countries.
In the Netherlands, however, prenatal screening tests for congenital defects are not offered routinely. The
present study aims to assess test uptake in a large, unselected population of pregnant women, and to give
more insight into the decision for or against prenatal screening through nuchal translucency measurement or
maternal serum screening.
Patients and Methods The study is part of a randomized controlled trial with two groups, each being offered
a different prenatal screening test, and a control group. Pregnant women received postal questionnaires at three
stages of their pregnancy.
Results Of the women being offered the nuchal translucency measurement or the second trimester maternal
serum test, 53 and 38% respectively accepted the test offer. The main reasons for accepting were ‘gaining
knowledge about the health of the foetus/curiosity’ (50%), ‘favourable characteristics of the screening test’
(18%), and ‘increased risk of having a child with DS’ (15%). The main reasons for declining were ‘unfavourable
characteristics of the screening test’ (42%), ‘not applicable/not necessary’ (35%), ‘anxiety/uncertainty’ (36%),
‘adverse characteristics of the invasive tests’ (32%), and ‘being against abortion’ (15%).
Discussion The uptake of prenatal screening was relatively low, and different distributions of reasons were
reported, compared to other studies. These differences may be due to the specific Dutch situation in which
prenatal screening is not part of standard prenatal care. The question arises as to whether informed decision-
making would be reduced if prenatal screening became routinised. Copyright  2005 John Wiley & Sons,
Ltd.
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INTRODUCTION
Prenatal screening can identify a high-risk subgroup
within a population of pregnant women. Prenatal screen-
ing for Down syndrome (DS) and neural tube defects
(NTD) provides an individualized risk estimation of hav-
ing a child with one of these disorders. The subgroup
of women with an increased risk can be offered prenatal
diagnostic testing in order to provide a certain diagnosis.
Two of the available methods of prenatal screening
for congenital defects are the nuchal translucency mea-
surement (NTM) and the maternal serum screening test
(MST). Although both screening tests result in a risk
estimation, it should be stressed that these tests have dif-
ferent characteristics: NTM screens only for DS in the
first trimester of pregnancy, and is performed through
ultrasound scanning (Nicolaides et al., 2002). The MST
(‘triple test’) is a blood test in the second trimester of
pregnancy, and tests for both DS and NTD (Benn, 2002).
*Correspondence to: Matthijs van den Berg, Institute for Research
in Extramural Medicine, Department of Public and Occupa-
tional Health, VU University Medical Center, Van der Boe-
chorststraat 7, NL-1081 BT Amsterdam, The Netherlands. E-mail:
m.vandenberg@vumc.nl
Although prenatal screening for DS and NTD has
become standard practice in many western countries,
this is not the case in the Netherlands. In July 1996,
the Population Screening Act (PSA) became law in the
Netherlands. Its purpose was to protect the population
against screening programmes that could be a threat
to the psychological and physical health of the person
being screened. One of the categories of the population
screening that requires ministerial approval is screen-
ing for ‘serious disorders that can neither be treated nor
prevented’. Prenatal screening for congenital disorders
comes under this category, since the legislature considers
termination of pregnancy as being neither treatment nor
prevention (Health Council of the Netherlands: Com-
mittee on the Population Screening Act, 1996). Since
there is no approval for this type of screening in the
Netherlands, it is forbidden to offer prenatal screening
to pregnant women, unless they request it. However,
permission is granted to offer prenatal diagnostic tests
to pregnant women only if they are over 35 years of age.
In contrast to the practice in other western countries,
in the Netherlands the prenatal care system is strongly
decentralized: midwives operate as autonomous medical
practitioners (Smeenk and ten Have, 2003). Generally,
physiological pregnancies are taken care of by midwives,
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and it is only in cases where pathology is suspected
or identified that the pregnancy is managed by a
gynaecologist (Pajkrt et al., 1998).
In the United States, prenatal screening has been
offered as part of customary prenatal care for decades,
and having such a screening test done has become com-
mon (Markens et al., 1999; Press and Browner, 1997).
On the basis of interviews and observations, Markens
et al. and Press and Browner concluded that prenatal
screening ceases to be something about which a delib-
erate decision needs to be made. A recently published
review by Green et al. on psychosocial aspects of pre-
natal and newborn screening, which included 106 pub-
lications from 12 different countries, also concluded
that women’s understanding of screening is poor and
that most women are not making informed choices
about screening (Green et al., 2004). Accepting prena-
tal screening is not a result of a considered, conscious
decision, but rather perceived as something self-evident:
‘Thus, the acceptance of routines because they are rou-
tine means that pregnant women do not necessarily
make an informed decision [. . .] ‘(Green and Statham,
1996). A Scottish report, which presents a technol-
ogy assessment concerning ultrasound scanning before
24 weeks of pregnancy (this includes NTM), also con-
cluded that many women did not feel that they were
being offered a choice about testing, and did not consider
their decision-making as being informed (Ritchie et al.,
2004). This lack of informed decision-making conflicts
with the commonly held belief that the objective of pre-
natal screening is to enable people to make their own,
informed decision regarding whether to have the screen-
ing test done or not, rather than preventing as many
affected children as possible from being born (Health
Council of the Netherlands, 2001; Marteau et al., 2001).
Uptake rates of screening tests are generally high in
countries where prenatal screening is part of usual care,
for example, in the United Kingdom, uptake percent-
ages were 87% for the second-trimester MST, and over
95% for NTM combined with first-trimester serum bio-
chemistry (Spencer, 1999; Spencer et al., 2000; Spencer
et al., 2003). Studies from other countries also reported
high uptake rates (Browner and Press, 1995; Jorgensen,
1995a; Press and Browner, 1998; Salonen and Ammala,
1997; Sanden and Bjurulf, 1988). However, uptake rates
vary considerably across health care settings, even in the
same region (Dormandy et al., 2002b).
Several studies that have been done to assess motiva-
tions concerning prenatal screening, focused solely on
reasons for declining the screening test (Bennett et al.,
1980; Berne-Fromell et al., 1984; Jorgensen, 1995b;
Liamputtong et al., 2003; Sher et al., 2003). These stud-
ies reported religious and moral reasons as the main
reasons for declining a screening test, as well the unre-
liability of the test. Some other studies examined only
reasons for accepting prenatal screening (Browner and
Press, 1995; Press and Browner, 1993; Roelofsen et al.,
1993; Santalahti et al., 1998; Weinans et al., 2000). The
most frequently mentioned reason in the majority of
these studies was reassurance (see also Green et al.,
2004).
Most of the above-mentioned studies were performed
in countries where prenatal screening is part of custom-
ary prenatal care. Given the questions about informed
choice in these countries, our study—which is per-
formed in a situation where this screening is not a rou-
tine or implicit decision—offers a unique opportunity to
investigate uptake and reasons for accepting or declin-
ing the screening offer in an unbiased way. According to
the PSA, ministerial approval was needed for this study,
since it involves offering prenatal screening.
The aim of this study is to assess the uptake of prenatal
screening tests offered to an unselected population of
pregnant women, and to assess how uptake differs across
the background variables. The second aim of the study
is to investigate reasons for either accepting or declining
prenatal screening for congenital defects.
PATIENTS AND METHODS
Women attending one of 44 participating midwifery and
gynaecology practices from May 2001 to May 2003
before 16 weeks’ gestation were asked permission to
be sent a research information letter and an informed
consent form. Women who granted informed consent
were randomized into one of two intervention groups or
into the control group. Women in the first intervention
group were offered the NTM, and women in the other
randomization group were offered the MST. Participants
in the control group received the customary care. As
the NTM has to be performed in the first trimester
of pregnancy, women whose first contact with their
midwife or gynaecologist occurred later than 10 weeks
into the pregnancy could be randomized solely in the
MST group or the control group.
The test offer consisted of a sent-home booklet
with information about the particular test, and an oral
explanation by the woman’s midwife or gynaecologist
during a personal consultation. The following topics
were covered in the information booklets: characteristics
of DS and NTD (information about NTD was covered
only in the MST booklet), age-specific risks of DS,
population risk of NTD, procedure of the screening
test, options available following a positive test result,
and procedure of the diagnostic tests (amniocentesis
and chorionic villus sampling). The last section of the
booklet was entitled as follows: ‘to decide whether or not
to undergo the screening test’. This section listed some
advantages and disadvantages of having the prenatal
screening test done. The booklets were pilot-tested for
clarity. Women who gave birth in the VU University
Medical Center during the year preceding the start of the
study (n = 659) were asked to read the booklet and fill
in a questionnaire. Of these women, 368 (58%) returned
the questionnaire. It appeared that the booklets were
comprehensible and suitable to be used as information
booklets in our study. After this pilot, the wording
of the booklets was adapted in some areas. The oral
explanation was standardized by means of a plasticized
paper consultation guide, which covered the same topics
as the information booklets as well as some counselling
Copyright  2005 John Wiley & Sons, Ltd. Prenat Diagn 2005; 25: 84–90.
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guidelines. These guidelines included issues of non-
directiveness: ‘avoid giving your own opinion’, ‘it has
to be the pregnant woman’s own decision’. A separate
visit to the hospital was required to have the screening
test done.
Data collection took place using five questionnaires.
For the present article, only data of the first three ques-
tionnaires were used. The first questionnaire was filled
in before the pregnant women received the screening
information booklet, and the second questionnaire was
filled in after they had read the booklet and decided for
or against prenatal screening, but (if applicable) before
they received the result of the screening test. The third
questionnaire was sent after receiving the result (or at a
comparable point in time).
The first questionnaire contained questions about
background variables such as age, education, parity,
and religion. The second questionnaire contained open-
ended questions in which participants were asked for
their personal reasons (including a decisive one) for
accepting or declining the prenatal screening offer. The
third questionnaire asked whether participants had had
the screening test done or not. Overall, these answers
matched the official result forms. The self-reported test
uptake rates were used in the analyses.
During the recruitment period, 4076 women were
asked to participate in the study; 2978 (73%) women
gave informed consent and returned the first question-
naire. Of these women, 74% (n = 2203) also filled
in and returned the second questionnaire (after one
reminder letter). The third questionnaire was returned
by 1968 women. For the present article, only data of
the respondents in the intervention groups were used
(n = 1399). For analysis of non-response, all women
who were asked to participate between September 2002
and January 2003 were sent a short questionnaire. Of
these 259 women, 130 (50%) replied. It appeared that
the main reason for not participating in the study was
lack of time or lack of interest.
Analysis
Categories and sub-categories for given reasons for
accepting or declining prenatal screening were cre-
ated by the first author on the basis of a selection of
hundred answers, and discussed by others (JHK, EG,
DRMT). After some adaptations had been implemented,
all answers were coded by three persons (MB, JHK, EG).
At random, 20% of the answers were double-coded into
the main categories by one of the authors (DRMT). The
correspondence rate was 94%. Most non-corresponding
codes were a result of a systematically different inter-
pretation by the double-coder of the meaning of three
of the 16 main categories. After some discussion, these
differences in interpretation were resolved.
To compare the distributions of test uptake with
respect to the background variables (age, education,
parity, and religion), and with respect to the two different
screening tests, χ2 tests were used. Ordinal variables
were analysed using a χ 2 test for trend (χ2trend ). Multiple
logistic regression was used for multivariate analysis.
Approvals
According to the Dutch Population Screening Act, the
Minister of Health, Welfare, and Sports had to grant
permission for this study to be performed. After receiv-
ing advice from the Health Council, the permission was
granted (Health Council of the Netherlands: Commit-
tee on the Population Screening Act, 1999). The present
study was also approved by the Ethical Committee of
the VU University Medical Center.
RESULTS
To assess the representativeness of the sample, back-
ground variables (age, education, and parity) were com-
pared with data of the general pregnant population in
the Netherlands (Statistics Netherlands, 2004). The only
relevant difference was that women in our sample had
higher education levels (19 and 43% for the general
pregnant population and our study sample respectively).
The mean age of the participants was 31 years.
Uptake
The overall test uptake was 46%. Table 1 shows the dis-
tribution of acceptors and decliners for the two screening
tests. Test uptake was significantly higher among women
being offered the NTM compared to those being offered
the MST (χ2 = 32.4, 1 df, p < 0.001). Table 2 shows
that test uptake was significantly lower for women who
reported being more actively religious and for women
who were highly educated. Using a model that started
with all four background variables, multiple logistic
regression analysis revealed that the degree of religios-
ity and level of education remained significantly and
independently associated with test uptake (see Table 3).
Reasons for accepting or declining the
screening test
The mean number of reasons for accepting or declining
prenatal screening that participants specified was 1.9.
The test acceptors gave significantly fewer reasons
compared to the test decliners (1.7 versus 2.0, t = 7.5,
p < 0.001). The participants were also asked to give one
Table 1—Numbers of participating pregnant women accepting








NTMa 387 (53)∗ 342 (47) 729
MSTb 254 (38) 416 (62) 670
Total 641 758 1399
a NTM, nuchal translucency measurement.
b MST: maternal serum screening test.
∗ χ2 = 32.4, p < 0.001.
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Table 2—Background characteristics of the participating preg-










<26 89 (7) 39 (44) 50 (56)
26–30 499 (37) 215 (43) 284 (57)
31–35 639 (47) 316 (50) 323 (50)
>35 123 (9) 49 (40) 74 (60)
χ2trend = 0.54, p = 0.463
Number of children
0 602 (43) 287 (48) 315 (52)
1 574 (41) 247 (43) 327 (57)
2 163 (12) 79 (49) 84 (51)
≥3 60 (4) 28 (47) 32 (53)
χ2trend = 0.15, p = 0.701
Degree of religiositya
Actively 58 (4) 12 (21) 46 (79)
Somewhat actively 255 (18) 105 (41) 150 (59)
Not actively 412 (30) 213 (52) 199 (48)
Not religious 668 (48) 306 (46) 362 (54)
χ2trend = 6.3, p = 0.012
Educational levela
Low 165 (12) 95 (58) 70 (42)
Middle 616 (45) 280 (46) 336 (54)
High 579 (43) 244 (42) 335 (58)
χ2trend = 10.1, p = 0.001
a The totals of age, degree of religiosity, and educational level do not
add up to 1399 because of missing values on these questions.
Table 3—Multiple logistic regression analysis: two significant
factors associated with test uptake
OR 95% CI
Degree of religiosity p < 0.001
Not religious 1.00
Not actively 1.29 1.00–1.66
Somewhat actively 0.82 0.61–1.11
Actively 0.34a 0.17–0.65




a significant at 0.01 level.
decisive reason, but 45% of the test acceptors and 33%
of the test decliners failed to give a decisive reason.
The respondents either did not fill in this question, or
they indicated that there was not one decisive reason.
So, the numbers of participants giving a decisive reason
are as follows: 353 (55% of 641) acceptors and 500
(66% of 758) decliners. Women’s (decisive) reasons for
accepting or declining prenatal screening are shown in
Table 4 and 5 respectively.
There were no differences in frequencies of deci-
sive reasons between the NTM group and the MST
group, except for the category ‘research/science’ with
regard to the acceptors (3% versus 13%, χ 2 = 12.4,
1 df, p < 0.001) and the category ‘unfavourable test
characteristics of the screening test’ with regard to







(n = 641) %
Decisive
reason













Wanting a healthy child 5 5
Reasons against testing 21 6
Other 36 21







(n = 758) %
Decisive
reason












Against abortion 15 13
Acceptance/destiny 16 10




the decliners (17% versus 26%, χ 2 = 5.9, 1 df, p <
0.05)
Test acceptors
The most frequently mentioned reason for accepting a
screening offer was ‘gaining knowledge about the health
of the foetus’ (50 and 39% as decisive reason). This
category included sub-categories such as ‘I just want to
know whether or not the child has Down syndrome’, ‘I
want more certainty about the health of the foetus’, and
‘It’s just out of curiosity’. Of the women who accepted
the screening offer, 18% mentioned that they did so
because of the favourable test characteristics (15% as
decisive reason). This category consisted of two sub-
categories: ‘The test does not involve any risk’, and
‘There’s no harm in trying’. Another group (15 and 12%
as decisive reason) decided to have the screening test
done because (they thought) they had an increased risk
of having a child with congenital defects, either because
of their age or because of family history. Reassurance
was mentioned by 8% of the women. The ‘Other’
category involved reasons such as ‘to be prepared’ and
Copyright  2005 John Wiley & Sons, Ltd. Prenat Diagn 2005; 25: 84–90.
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‘the ability to make a better choice concerning invasive
diagnostic testing’.
Test decliners
The main reasons for declining a screening test were
‘unfavourable characteristics of the screening test’
(42%), ‘anxiety/uncertainty’ (36%), ‘not applicable/not
necessary’ (35%), and ‘adverse characteristics of the
invasive tests’ (32%). Almost a quarter of all women
mentioned ‘unfavourable characteristics of the screen-
ing test’ as their decisive reason for refusing prenatal
screening. This reason contained three sub-categories:
‘It is just a calculation of probability’, ‘The test gives
no certainty’, and ‘The test is not reliable’. Another
important reason concerned the feeling in women that
screening causes anxiety and uncertainty. The three most
frequent sub-categories were ‘I do not want to become
unnecessarily anxious’, ‘The test result will make me
uncertain and anxious’, and ‘I am afraid of a positive
test result’. Relevant sub-categories within the group of
women who considered screening as ‘not applicable’ or
‘not necessary’ were ‘I am not in a risk group’ and ‘I
have already done a prenatal test’. The fourth main rea-
son women gave was coded as ‘adverse characteristics
of invasive tests’. This category included the following
sub-categories: ‘I will not do diagnostic testing because
of the risk of miscarriage that is involved’ and ‘I do not
want to make a possibly difficult decision’.
Among the reasons for declining the screening test,
two ethical reasons could be discerned: women who
were opposed to selective abortion (15%), and women
who see the health status of the baby as destiny or fate,
and would accept the child anyway (16%). This last
reasoning included the following sub-categories: ‘The
child is welcome, whether it is disabled or not’ and ‘I
want nature to take its course’.
Ambivalence in reasoning
Of the test accepters, 21% also mentioned reasons
against prenatal screening, in addition to reasons in
favour of prenatal screening (Table 4). The most fre-
quently mentioned reasons were ‘adverse characteristics
of invasive test’, and ‘anxiety/uncertainty’. On the other
hand, 17% of the women who declined the screen-
ing offer also mentioned reasons in favour of screen-
ing (Table 5). The contra-reasons among test decliners
included ‘gaining knowledge/curiosity’, ‘increased risk
of having a child with DS’, and ‘favourable characteris-
tics of the screening test’.
DISCUSSION
The overall uptake of prenatal screening for congenital
defects was 46%. This is considerably lower than most
other studies report. Some studies presented uptake rates
of 90% and above (Spencer et al., 2003). These dif-
ferences in uptake are probably related to the different
situation in the Netherlands compared to other countries.
Generally in the Netherlands, prenatal care is not consid-
ered as something ‘medical’, and the natural character of
pregnancy is highly valued (Roelofsen et al., 1993). This
is evident not only from the high rate of home deliver-
ies and the low rate of epidural analgesia during labour
in the Netherlands but also from the fact that prenatal
screening is not part of customary care. Consequently,
accepting the screening test offer is not a routine decision
for Dutch pregnant women. These factors might account
for the relatively low uptake rates of prenatal screening.
Nevertheless, two Dutch studies did report high uptake
rates of around 80% (Kamerbeek et al., 1993; Muller
et al., 2002). The study of Kamerbeek et al. was per-
formed in a particular region of the Netherlands, where
prenatal screening was offered routinely even though this
is not allowed formally. In contrast to our study, in the
study of Muller et al., no separate visit was required
to have the screening test done. Dormandy et al. have
shown that higher uptake of serum screening was seen
at hospitals that offered the test as part of a routine
visit than at those where screening required a separate
visit (Dormandy et al., 2002a, b). It might be that pre-
natal screening as part of a routine visit stimulates test
uptake without giving too much thought to it (Press and
Browner, 1997; Tymstra et al., 1991). However, it could
also reflect barriers to testing incurred by requiring a
separate visit (Dormandy et al., 2002a).
In our study, uptake rates of 53% for the NTM and
38% for the MST were found. Because there were
hardly any differences in given reasons between the
two groups, other factors may be relevant in explaining
these different uptake rates. It might be related to
the fact that the NTM is performed by ultrasound
scanning, resulting in the visualization of the foetus,
which is often seen as an advantage of this screening
test. In general, pregnant women consider ultrasound
examination as a benign procedure, allowing them to
see their baby, and they attach positive value to being
able to see it (Baillie et al., 1999; Green and Statham,
1996; Ritchie et al., 2004). Another contributing factor
could be women’s preferences for screening in the first
trimester of pregnancy (NTM) compared to screening
in the second trimester (MST) (de Graaf et al., 2002;
Kornman et al., 1997).
The three most frequently mentioned reasons for
accepting the screening test offer (obtaining knowledge,
good test characteristics, increased risk) did not include
reassurance. However, other studies (Santalahti et al.,
1998; Browner and Press, 1995; Roelofsen et al., 1993)
reported reassurance as the most important reason for
having a screening test done. This might be due to a
difference in information given in the booklet women
received, or in the counselling by their midwife or
gynaecologist. In our study, participants received well-
balanced information about the pros and cons of the
screening tests, while this may not always be the case in
countries where prenatal screening is part of customary
prenatal care. Consequently, it could be that women
participating in our study were more aware of the fact
that a screening test is not able to give reassurance by
itself, since it provides merely a risk estimation.
Copyright  2005 John Wiley & Sons, Ltd. Prenat Diagn 2005; 25: 84–90.
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Two of the main arguments for declining the screen-
ing test offer (mentioned by three quarters of the parti-
cipants) were linked to disadvantageous test character-
istics. The unfavourable characteristic of the screening
tests is that they provide only a risk estimation, and can-
not give certainty. On the other hand, a risk of induced
miscarriage of the foetus is inherent in diagnostic test-
ing. Women specifying one of these reasons were not
opposed to prenatal screening in general, and did not
consider it problematic to know the health status of their
baby, but they basically said ‘the test isn’t good enough’,
or they just did not want to put their baby at risk. These
data suggest that many pregnant women will make a dif-
ferent decision when a risk-free screening test providing
a certain diagnosis is available. Accordingly, we expect
higher uptake rates in the future when better screening
tests will have been developed.
Of the women, 23% mentioned reasons against
screening that could be interpreted as ethical in nature.
This percentage is considerably lower than reported by
Sher et al. (2003). Cultural and religious differences may
be responsible for this difference. Furthermore, it might
be due to the fact that at the time the study by Sher et al.
was carried out, screening had already become widely
accepted. In such a situation, declining prenatal screen-
ing may mainly be based on strong moral values. Again,
the well-balanced information booklets may also play a
part here.
Over 25% of the women also gave reasons in support
of the opposite decision option. On the one hand, this
could be an indication of ambivalence: the choice of
whether or not to screen is not a clear-cut decision, but
rather one that is imbued with mixed feelings. In this
case, these women need to be given special attention
during the counselling process. On the other hand, it
may also be an indication of someone balancing the pros
and cons of a decision. In this situation, giving opposite
reasons might be a sign of a rational, informed decision
(Bekker et al., 2003).
To conclude then, offering prenatal screening in a
context where it is not part of routine prenatal care
resulted in lower uptake rates and different reasons for
accepting or declining such a screening test than in a
situation in which screening is offered routinely. This
raises the question as to what extent a high uptake rate
involves a high number of informed choices. Are all test
acceptors making considered, deliberate decisions?
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